CapsoVision Reports Second Quarter 2026 Financial Results

SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.

Recent Highlights * Reported second quarter 2026 revenue was $3.6 million, up 10% year over year. * CapsoCam Plus® used by over 176,000 patients as of June 30, 2026. * Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system. * Anticipate FDA clearance of AI Highlights™ by the end of the third quarter of 2026, with U.S. commercial launch expected shortly thereafter. * Continued commercial momentum with expanding adoption across large hospital systems and GI networks, including key customer renewals and growing traction with new customers. * Pipeline continues to advance with CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026, with ongoing enrollment in the CapsoCam UGI clinical study for pancreatic cancer detection. * Appointed David S. Shields, M.D., to the Board of Directors, effective July 1, 2026. * Entered into a sales agreement of up to $100 million providing for an at-the-market equity offering program with Cantor. Management Commentary